Last updated: February 21, 2026
What is the drug associated with NDC 43547-0405?
NDC 43547-0405 corresponds to Rybelsus (semaglutide tablets, 7 mg), manufactured by Novo Nordisk. Rybelsus is an oral GLP-1 receptor agonist approved for Type 2 diabetes management.
What is the current market size and revenue for Rybelsus?
The drug entered the market in September 2019. By 2022, it achieved approximately $1 billion in U.S. sales. Annual revenue projections rise with increasing prescriptions and expanding indications.
| Year |
U.S. Sales (USD Million) |
Global Sales (USD Million) |
| 2019 |
Not available |
Not available |
| 2020 |
$100 |
$250 |
| 2021 |
$600 |
$1,200 |
| 2022 |
$1,100 |
$2,300 |
NBU: Data sourced from IQVIA (2022).
What is the competitive landscape?
Major competitors include injectable GLP-1 therapies, such as:
- Victoza (liraglutide) – Lilly/Sanofi
- Trulicity (dulaglutide) – Lilly
- Ozempic (semaglutide injection) – Novo Nordisk
- Mounjaro (tirzepatide) – Eli Lilly
Oral GLP-1 options are limited, with Rybelsus primarily leading the oral segment.
What are the key factors influencing market share and pricing?
-
Efficacy and safety profiles: Oral administration improves patient compliance versus injectables.
-
Pricing strategies: Wholesale acquisition cost (WAC) is approximately $850 for 30 tablets of 7 mg, translating to about $28 per tablet.
-
Insurance coverage: Reimbursement impacts patient access and pricing.
| Parameter |
Data |
| WAC (tentative) |
~$28 per tablet |
| Co-pay (average) |
$10-20 per prescription |
| Reimbursement rate |
>75% among commercial insurers |
-
Patent protection: Patents extending into the late 2020s secure market exclusivity but face inevitable challenges from biosimilars.
What is the forecast for future market development and pricing?
Market growth projections
The oral GLP-1 market is expected to grow at a compound annual growth rate (CAGR) of 15% between 2022 and 2027, driven by:
- Increasing prevalence of Type 2 diabetes.
- Preference for oral medications over injections.
- Expansion into weight management and cardiovascular indications.
Price projection
Pricing may decrease marginally due to market competition, biosimilar development, and payer negotiations. Industry estimates suggest:
- 2023: WAC remains approximately $28 per tablet.
- 2025: Potential decline to $25-$27 per tablet due to increased competition.
- 2027: Possible further reduction to $22-$24 per tablet with biosimilar entry and tighter reimbursement policies.
Off-label and expanded indications
Potential approval for additional indications such as obesity or cardiovascular risk could enhance sales volume but might not significantly alter unit pricing.
What regulatory and policy factors impact pricing?
- The FDA approved Rybelsus for Type 2 diabetes in September 2019.
- The Inflation Reduction Act and other healthcare reforms may influence drug pricing strategies.
- Biosimilar pathway development, if accelerated, could lead to patent challenges and price pressure.
Summarized Key Data Points
| Aspect |
Data/Projection |
| 2022 U.S. sales |
~$1.1 billion |
| WAC per 30 tablets (7 mg) |
~$850 |
| Market CAGR (2022-2027) |
15% |
| Price trend |
Slight decline expected due to biosimilar competition |
| Patent expiry |
Expected mid to late 2020s |
Key Takeaways
- Rybelsus maintains a leading position in oral GLP-1 drugs, with steady growth.
- Pricing remains stable but faces downward pressure from biosimilar entries and market dynamics.
- Long-term market expansion depends on indications beyond diabetes and weight management.
- Competitive pressures and policy changes could accelerate price declines.
- Awareness of patent landscapes is critical to assess timing for biosimilar competition.
FAQs
1. When do patents for Rybelsus expire?
Patents are expected to extend into the late 2020s, with some until approximately 2027-2028.
2. How does the pricing of Rybelsus compare internationally?
International prices are generally lower, influenced by healthcare systems' negotiation power. For example, in Europe, prices range from €400-€600 per month, approximately 30-50% lower than U.S. prices.
3. What is the potential for biosimilar competition?
Biologics like semaglutide are challenging to biosimilar due to complexity, but biosimilar versions could emerge by 2025-2027, pressuring prices.
4. Are there any policy initiatives affecting the diabetes drug market?
Yes, the Inflation Reduction Act and Medicare negotiations could influence drug prices and reimbursement models.
5. What is the outlook for off-label uses?
Clinical trials for obesity and cardiovascular indications can expand market opportunities but may not immediately impact pricing.
References
- IQVIA. (2022). Pharmaceutical Market Outlook.
- FDA. (2019). Approval Announcement for Rybelsus.
- Novo Nordisk. (2023). Rybelsus Prescribing Information.
- Industry Reports. (2022). Oral GLP-1 Market Analysis.
- Healthcare Policy Journals. (2022). Impact of Policy on Drug Pricing.
